Gekko, thank you for sharing your perspective, which raises valid concerns about the company's history and current standing.
Indeed, a track record of lengthy time-to-market, limited sales, and shareholder value erosion could unsettle any investor. You're right; past performance has been far from rewarding, and the lack of communication or apparent progress can be upsetting.
However, it's also worth considering that the biotech sector is inherently high-risk and long-term, often requiring many years of R&D, regulatory approvals, and clinical trials before a company can generate sustainable revenue.
Furthermore, gaining approval from a body like the GBA for clinical trials could signify a turning point, marking the company's transition from a research-focused to a commercial stage.
It's essential to be cautious, and your concerns are a critical part of the broader investment discussion. However, for those who believe in the company's technology and its potential impact on patient care, such turning points could offer a new opportunity, despite the checkered past.
As always, due diligence and risk assessment are key when considering any investment.
- Forums
- ASX - By Stock
- OSL
- Ann: Entitlement Offer to raise up to $9.9 million
Ann: Entitlement Offer to raise up to $9.9 million, page-162
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.58M |
Open | High | Low | Value | Volume |
0.9¢ | 1.0¢ | 0.9¢ | $99.72K | 11.05M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 6025000 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 2885714 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1320 | 0.009 |
10 | 7525000 | 0.008 |
20 | 11334962 | 0.007 |
20 | 22449999 | 0.006 |
24 | 20207000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 2885714 | 3 |
0.010 | 12280355 | 16 |
0.011 | 3318666 | 5 |
0.012 | 7294245 | 8 |
0.013 | 7981519 | 3 |
Last trade - 13.12pm 22/07/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |